Two state-of-the-art quality control (QC) laboratories in Basel and Visp are now fully operational and GMP-certified.

This follows a successful expansion by Swiss-based contract development and manufacturing organization (CDMO) ten23 health. The company marked the launch with an inaugural event attended by regional industry leaders and government representatives.

The newly licensed QC capabilities build on ten23’s integrated service offering, which spans early formulation and analytical method development to GMP manufacturing of clinical and commercial sterile products. With the addition of QC release and stability testing, customers now benefit from a streamlined solution that supports products from development through to market.

In Basel, the QC laboratory focuses on analytical services including method validation, method transfer, release testing, and stability testing under intended and accelerated storage conditions. Equipped with advanced technologies such as liquid chromatography and capillary electrophoresis, the lab conducts identity, purity, and content assays alongside compendial testing for parenteral products – covering key parameters like visible particles, pH, osmolality, clarity, and density. These services are applicable across a range of sterile formats including biologics, peptides, small molecules, bioconjugates, and oligonucleotides.

The Visp site adds dedicated microbiological and in-process control testing to the offering. Capabilities include bioburden and endotoxin analysis, sterility testing, microbial challenge studies, and low endotoxin recovery studies -critical for ensuring the safety and compliance of injectable therapies.

Dr Susanne Jörg, chief customer delivery officer, said: “Having obtained the GMP licenses for our QC services laboratories in both Basel and Visp represents a pivotal moment for ten23 health and underscores our dedication to Swiss excellence in providing integrated services for pharmaceutical development, manufacturing, and testing.”

QC services are now available as stand-alone solutions or bundled with development and fill-finish manufacturing, enabling clients to benefit from a high level of integration across sites and services.

Ivana Heckel, head of QC, added: “We are pleased to announce this milestone, which further strengthens our position as an integrated, highly knowledgeable, and trusted partner for sterile dosage forms in the CDMO landscape.”

With this expansion, ten23 reinforces its position in the European sterile manufacturing sector, offering pharmaceutical partners a single, compliant route from concept to clinic and beyond.